Altre lingue Yabao Pharmaceutical Group Co., Ltd

Azioni

600351

CNE000001CM5

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 22/05/2024			Variaz. 5gg	Var. 1 gen.
6,46 ^CNY	-0,77%		-3,29%	-6,38%

25/04	Yabao Pharmaceutical Group Co., Ltd riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
25/04	Yabao Pharmaceutical Group Co., Ltd riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules	16/04
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	02/04
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.	05/02
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	10/10/23
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index	18/09/23
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd	18/09/23
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan	08/08/23
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	03/08/23
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	04/07/23
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.	09/05/23
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug	13/04/23
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets	16/11/22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor	03/08/22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Yabao Pharmaceutical Group Co., Ltd

Azioni

600351

CNE000001CM5

Altre lingue

Filtri